Please provide your email address to receive an email when new articles are posted on . In a cross-sectional analysis of adults who attended outpatient clinics at the University of Florida in ...

Please provide your email address to receive an email when new articles are posted on . More than half of patients with baseline fatty liver disease experienced a reduction in hepatic steatosis after ...

A New Category on the Steatotic Liver Disease SpectrumIn a comprehensive review published in eGastroenterology , Professor Gao from the NIAAA/NIH and ...

Liver steatosis is more prevalent than liver fibrosis in people with HIV, with significant risk factors including age, hypertension, and diabetes. Liver fibrosis prevalence is low, with integrase ...

Researchers have found in a secondary analysis of a clinical trial published in Obesity that taking dapagliflozin 10 mg daily ...

“MASLD and T2DM represent intersecting global epidemics with substantial clinical and public health implications,” wrote the ...

A nationwide, population-based cohort study of patients with imaging-confirmed hepatic steatosis assessed the long-term risks associated with three distinct steatotic liver disease subtypes. Liver and ...

Hepatic steatosis, often triggered by non-alcoholic fatty liver disease (NAFLD), is a leading cause of liver dysfunction globally, affecting approximately 30% of the population. The progression from ...

In a recent study published in Clinical Gastroenterology and Hepatology, researchers quantified the adverse effects of fast-food intake on liver steatosis. Study: Quantifying the Negative Impact of ...

Juxtapid has been available to treat adults with homozygous familial hypercholesterolemia (HoFH), a rare genetic disorder that causes extremely high levels of LDL cholesterol.